This osteoporosis panel includes:

• Serum total calcium, albumin (to calculate albumin adjusted calcium) and phosphorus as part of a CMP panel to detect conditions associated with hypercalcemia such as primary hyperparathyroidism or hypocalcemia and consequent secondary hyperparathyroidism causing bone loss
• Serum creatinine and estimated glomerular filtration rate (GFR) as part of the CMP panel are useful to detect renal failure which can affect bone health. 
• Serum alkaline phosphatase (ALP) as part of a CMP panel. ALP measurement is useful to detect conditions including Paget's disease, metastatic bone disease and osteomalacia, etc.
• Vitamin D nutrition should be determined by measuring serum 25-hydroxy vitamin D [25(OH)D]. Although there is controversy about the optimum level of 25(OH)D for bone health; while 50 nmol/L is considered acceptable
• Parathyroid Hormone (PTH) measurement would be required if serum calcium is abnormal, to help investigate the cause of the calcium abnormality.
• Ultra-sensitive Estradiol. Low estradiol in men and women has been linked to bone loss.
• Phosphorus. An increased phosphorus with decreased calcium suggests either hypoparathyroidism or renal disease. A decreased phosphorus and an increased calcium suggests hyperparathyroidism or sarcoidosis. When both calcium and phosphorus are decreased diagnostic considerations include malabsorption, vitamin D deficiency and renal tubular acidosis. Increased phosphorus and normal or increased calcium suggests Milk-alkali syndrome or hypervitaminosis D.